Sarepta Therapeutics Shares Slide Amid Analyst Downgrades

Sarepta Therapeutics shares are trading lower after BMO Capital downgraded the stock to Market Perform with a reduced price target of $70, citing safety concerns related to their Elevidys treatment. Additionally, Piper Sandler downgraded their rating to Neutral with a lowered price target of $36.